Skip to main content

Table 2 Anti tumor effect

From: A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma

Over all
  CR PR NC PD Response Rate (%)95%C.I. CR+PR/TOTAL Clinical Response (%)95%C.I. CR+PR+NC/TOTAL
Over all 0 18 13 11 42.9 (27.7–59.0) 73.8 (58.0–86.2)
BDca 0 11 10 6 40.7 (22.4–61.2) 77.8 (57.8–91.4)
GBca 0 7 3 5 46.7 (21.1–73.5) 66.7 (38.4–88.2)
Primary or local recurrence
  CR PR NC PD Response Rate (%)95%C.I. CR+PR/TOTAL Clinical Response (%)95%C.I. CR+PR+NC/TOTAL
Over all 0 14 8 6 50.0 (30.6–69.4) 78.6 (59.0–91.7)
BDca 0 9 6 3 50.0 (26.0–74.0) 83.3 (58.6–96.5)
GBca 0 5 2 3 50.0 (18.6–81.4) 70.0 (34.7–93.5)
Metastatic lesion
  CR PR NC PD Response Rate (%)95%C.I. CR+PR/TOTAL Clinical Response (%)95%C.I. CR+PR+NC/TOTAL
Over all 0 10 12 9 32.3 (16.7–51.4) 71.0 (52.0–85.8)
BDca 0 6 9 5 30.0 (11.8–54.3) 75.0 (50.9–91.4)
GBca 0 4 3 4 36.4 (10.8–69.3) 66.7 (30.7–89.2)
  1. Abbreveations
  2. BDca: bile duct carcinoma, GBca: Gallbladder carcinoma